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Abstract
The correct balance between proteases and their natural protein inhibitors is of great importance in living
systems. Protease inhibitors usually comprise small folds that are crosslinked by a high number of disulfide
bonds, making them perfect models for the study of oxidative folding. To date, the oxidative folding of nu-
merous protease inhibitors has been analyzed, revealing a great diversity of folding pathways that differ mainly
in the heterogeneity and native disulfide-bond content of their intermediates. The two extremes of this diversity
are represented by bovine pancreatic trypsin inhibitor and hirudin, which fold, respectively, via few native
intermediates and heterogeneous scrambled isomers. Other proteins, such as leech carboxypeptidase inhibitor,
share characteristics of both models displaying mixed folding pathways. The study of the oxidative folding of
two-domain inhibitors, such as secretory leukocyte protease inhibitor, tick carboxypeptidase inhibitor, and
Ascaris carboxypeptidase inhibitor, has provided some clues about how two-domain protease inhibitors may
fold, that is, either by folding each domain autonomously or with one domain assisting in the folding of the
other. Finally, the recent determination of the structures of the major intermediates of protease inhibitors has
shed light on the molecular mechanisms guiding the oxidative folding of small disulfide-rich proteins. Antioxid.
Redox Signal. 14, 97–112.
Introduction
Proteolytic enzymes, commonly referred to as proteases,are essential in nature for the survival of all living or-
ganisms. Despite their important physiological functions,
enzymes that cleave other proteins are potentially very
damaging to their environment, so their activities must be
kept strictly under control. Distinct mechanisms exist for the
regulation of the catalytic activity of proteases, very important
among them being the interactions of proteases with their
protein inhibitors (17). Protein inhibitors of proteolytic en-
zymes comprise the largest and structurally most diverse
group of naturally occurring enzyme inhibitors. A compre-
hensive list of the different inhibitor families is available
on the web at http:==merops.sanger.ac.uk= (62). Protease in-
hibitors are usually classified either by their mechanisms
of action, which are surprisingly diverse, or by the type of
protease they inhibit, that is, serine, cysteine, aspartic, or
metalloproteases—protein inhibitors of threonine and gluta-
myl proteases are yet to be discovered [for review, see (58,
63)]. Protease inhibitors are often small in size, with one or
multiple tandem domains, and are crosslinked by several
disulfide bonds. These characteristics provide protease in-
hibitors with high stability and a long half-life and make
them very attractive models for the study of protein folding.
Besides enzymes such as ribonuclease A (RNase A) and
lysozyme, growth factors, and toxins [for review, see (2)],
numerous serine and metalloprotease inhibitors have been
investigated using the technique of oxidative folding.
Oxidative folding is the in vitro process by which a fully
reduced and unfolded protein gains both its native disulfide
bonds (disulfide-bond formation) and native structure (con-
formational folding). The folding processes of many protease
inhibitors can be efficiently tracked owing to the small and
disulfide-rich nature of their protein folds. Thus, their folding
intermediates are chemically trapped in a time-course man-
ner, either irreversibly by alkylation or reversibly by acidifi-
cation, and further analyzed=purified by reversed-phase
chromatography [for review, see (55)]. The isolation of these
partially folded species allows their characterization in terms
of disulfide-bond connectivity (number and type—native or
nonnative) and structure. The derived information will help
to define the studied protein’s oxidative folding pathway
on the basis of the following features: (i) the extent of the
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heterogeneity of folding intermediates, (ii) the predominance
of intermediates containing native disulfide bonds and
native-like structures, and (iii) the presence of scrambled
isomers (fully oxidized species containing at least two non-
native disulfides) as intermediates along the folding reaction
(32, 33). The two opposite extremes of the oxidative folding
pathways are exemplified by proteins that fold through the
formation of a few intermediates adopting native disulfide
bonds, and proteins that fold via highly heterogeneous inter-
mediates containing nonnative disulfides, that is, their folding
pathways are populated by scrambled isomers (Fig. 1). On the
other hand, other proteins share similarity and dissimilarity
with both models, displaying mixed folding pathways.
The present work reviews the pathways of oxidative fold-
ing reported thus far for single- and two-domain protease
inhibitors. The determinants that account for the large di-
versity of folding landscapes in these proteins are discussed,
together with the recent structural determination of disulfide
intermediates that provide fundamental insights into a better
understanding of oxidative folding.
Oxidative Folding via Few Native Intermediates
Bovine pancreatic trypsin inhibitor
Bovine pancreatic trypsin inhibitor (BPTI) is a 58-residue
serine protease inhibitor linked by three disulfide bonds:
Cys5-Cys55, Cys14-Cys38, and Cys30-Cys51 (Fig. 2). Crystal
and solution structures of BPTI and a number of engineered
variants have shown that it is a compact molecule with a
double-stranded antiparallel b-sheet, two short segments of a-
helix, and a small hydrophobic core (16, 50, 51). BPTI was,
together with RNase A, one of the first models for which the
characterization of folding pathways was addressed. It has
been thoroughly studied for more than three decades, and the
conformational features and kinetic roles of all its relevant
folding intermediates are already known, making this mole-
cule an outstanding model to understand the structural, se-
quential, and kinetic determinants that drive oxidative
folding (23, 24, 29, 39, 78, 79).
Disulfide bonds are essential for BPTI folding, function,
and stability. Although the reduced inhibitor is mostly un-
folded (40), several studies converge to indicate that this state
is not a random coil but exhibits some native-like conforma-
tional preferences and local interactions between certain res-
idues close in sequence (44, 46). These contacts appear to be
strong enough to compensate for the loss of conformational
entropy in the unfolded state, although they display reduced
stability and are transient, which means that they may be
easily broken during subsequent conformational folding (28).
Pioneering studies on the oxidative folding of BPTI were
conducted by Creighton and coworkers. They exploited the
high reactivity of free cysteines at slightly basic pH to trap by
alkylation the different populations of folding intermediates
that accumulate along the folding pathway (23, 25, 26). This
work revealed that reduced and unfolded BPTI forms its
initial disulfide bonds almost randomly, rendering a hetero-
geneous population of 1-disulfide (1S) molecules. The 1S
population subsequently rearranges by intramolecular dis-
ulfide exchange (reshuffling) into predominant 1S interme-
diates, reaching equilibrium before the formation of the
second disulfide bond. Although BPTI can form 15 different
1S species, the ensemble is dominated by a species containing
a native disulfide between Cys30 and Cys51, designated as
[30–51]. The predominance of [30–51] is due to the fact that, in
contrast to most of the other 1S species, it adopts a partly
folded structure that endows it with the lowest free energy in
the ensemble. The conformation of [30–51] is thought to re-
semble that of native BPTI, with the disulfide bond linking the
two major secondary structure elements. The interaction be-
tween the b-sheet and the a-helix stabilizes the protein and at
the same time protects the disulfide bond. The rest of the
polypeptide chain remains very flexible (75). In kinetic terms,
the shielding of the Cys30–Cys51 disulfide bond results in a
slower breakdown ratio compared with the rest of the bonds
in other 1S species, and accordingly, all subsequently formed
intermediates in the folding pathway maintain this formed
bond.Under the conditions used byCreighton and coworkers,
a strong conformational bias is observed, since the other na-
tively bonded species represented only 3% of the ensemble, as
in the case of [5–55], or simplywere not detected, as in the case
of [14–38]. The [30–51] intermediate readily oxidizes two of its
free cysteines, producing threemajor 2S species, [30–51, 5–38],
FIG. 1. Oxidative folding pathways of divergent models. Folding intermediates of leech-derived tryptase inhibitor (LDTI)
(A), potato carboxypeptidase inhibitor (PCI) (B), and leech carboxypeptidase inhibitor (C) trapped by acidification at selected
time points and further analyzed by reversed-phase high-performance liquid chromatography. R and N indicate the elution
positions of the fully reduced=unfolded and native forms, respectively. ‘‘a’’ and ‘‘b’’ stand for intermediates containing
exclusively native disulfide bonds. ‘‘X’’ represents a highly heterogeneous population of scrambled isomers, that is, species
containing nonnative disulfide bonds.
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[30–51, 5–14], and [30–51, 14–38], among which only the last
one contains two native disulfide bonds; that is, it may be
termed des[5–55]. Although the formation of the Cys5–Cys55
disulfide bond in des[5–55] would lead to native BPTI, this
step finds a high energy barrier for its completion due to the
highly folded structure of this intermediate. In contrast, this
intermediate can rearrange its second disulfide bond to form
either of the nonnative Cys5–Cys14 or Cys5–Cys38 bonds and
therefore is in rapid equilibrium with the other two 2S inter-
mediates. Subsequently, in the slowest intramolecular reac-
tion of the pathway, these two intermediates reshuffle their
nonnative disulfide bonds to render [30–51, 5–55], which
contains two of the three native BPTI disulfides (des[14–38]).
In this intermediate the free thiols of Cys14 and Cys38 are on
the surface and spatially close, and may oxidize rapidly to
form the native inhibitor.
Weissman and Kim investigated BPTI folding with a
different experimental approach using acid-trapping and
reversed-phase high-performance liquid chromatography
analysis of the intermediates. They proposed a revised path-
way for the oxidative folding of this inhibitor, which, in
contrast to that proposed by Creighton and coworkers, is
characterized by the absence of stable intermediates contain-
ing nonnative disulfide bonds (Fig. 2, model a vs. b) (78, 79).
FIG. 2. Oxidative folding of bovine pancreatic trypsin inhibitor (BPTI)-like proteins. The amino acid sequence, sec-
ondary structure elements, and disulfide pairings of BPTI (3 SS and 58 residues), LDTI (3 SS and 46 residues), and Momordica
cochinchinensis trypsin inhibitor II (MCoTI-II; 3 SS and 34 residues) are schematically shown. The Protein Data Bank ID codes
for the structures of BPTI, LDTI, and MCoTI-II are, respectively, 1PIT, 1LDT, and 1IB9 (ribbon plots prepared with program
PyMOL). The disulfide bonds are shown as black sticks. An overview of the oxidative folding pathway of BPTI [models
proposed by Creighton and coworkers (a) and Weissman and Kim (b)], LDTI, and MCoTI-II is shown below each sequence. R
and N indicate the fully reduced=unfolded and native forms, respectively. The disulfide pairings of major folding inter-
mediates are shown between parentheses, and the missing disulfides between parentheses with the prefix ‘‘des’’ (des species).
1S and 2S are ensembles of molecules with the corresponding number of disulfide bonds.
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This results in a less heterogeneous pathway with only six
significantly populous intermediates. The 1S population ini-
tially forms its disulfide bonds almost randomly, but then
reshuffles rapidly to render two natively bonded species: the
already-described [30–51] intermediate and a new interme-
diate [5–55], which also likely possesses a folded conforma-
tion. In both forms, the free Cys14 and Cys38 would be
located in flexible regions preferentially exposed to solvent
when compared with the accessibility of the other two free
thiols. Accordingly, the formation of the Cys14–Cys38 dis-
ulfide in this 1S species would render only two 2S interme-
diates: [5–55, 14–38] (named des[30–51] or N*) and [30–51, 14–
38] (named des[5–55] or N0). These two forms act as strong
kinetic traps, freezing the folding reaction. Importantly, only
half of the unfolded and reduced BPTI molecules are able to
fold productively into the native form. The rest of the protein
remains kinetically trapped as N*. Different structural studies
have shown that N* has a native-like conformation in which
the free thiols of Cys30 and Cys50 are buried and protected
from the solvent, which precludes their oxidation. In this way,
N* is defined as an off-pathway intermediate that is stable for
weeks in this conformation. Confirming this view, it has been
recently reported that redox conditions that disfavor the ac-
cumulation of N* tend to accelerate and increase the pro-
ductivity of the BPTI folding reaction (52). As observed by
Creighton and coworkers, N0 is a well-folded intermediate in
which the missing disulfide bond between Cys5 and Cys55
cannot be directly formed to render the native BPTI structure.
According to Weissman and Kim, the burial of the reactive
cysteine residues inside the N0 structure forces this interme-
diate to unfold, to gain its native conformation. However,
fluctuations inside the N0 structure promote a rearrangement
reaction in which the free thiols attack the already formed
disulfides in the intermediate and promote the conversion of
N0 into N* and the [5–55, 30–51] intermediate (named des[14–
38] or NSH-SH). The stability of the N0 structure makes un-
folding reactions energetically expensive so that the rate of
this rearrangement is slow. In addition, the formation of N*
and NSH-SH from N0 is not a direct reaction but implies the
creation of a transient population of two intermediates con-
taining nonnative disulfide bonds, [30–51, 5–14] and [30–51,
5–38], which correspond to the productive nonnative inter-
mediates in Creighton’s scheme. Once NSH-SH is formed, as
described above, the flexibility and accessibility of the free
Cys14 and Cys34 thiols allow rapid oxidation to form the
native protein.
The disparity in the BPTI folding pathways proposed by
both laboratories conforms to the different solution conditions
in which the refolding reactions were performed and the
different strategies used to trap and analyze the intermedi-
ates. With time, Weissman and Kim’s view has prevailed and
BPTI is considered the archetype of a disulfide-rich protein in
which the folding pathway proceeds rapidly through the
formation of a limited number of stable, native-like interme-
diates in the absence of scrambled isomers.
An important point raised by Creighton and coworkers is
that inside the cell BPTI is synthesized as a pre-pro-inhibitor,
containing a 22-residue pre N-terminal extension that leads to
its translocation into the endoplasmic reticulum and two pro-
segments of 13 and 7 residues at the N- and C-terminal sides
of the mature sequence, respectively. It is not the mature form
that folds in the endoplasmic reticulum but the pro-inhibitor.
The pro-segment contains a cysteine residue that has been
shown to react with the mature BPTI cysteines (80). However,
no significant differences were observed between the folding
rates of mature and pro-BPTI in microsomes (27) and the
truncation of the side chain of the pro-segment’s cysteine by
mutation to serine did not affect the folding reaction either.
Unfortunately, a detailed picture of the folding pathway of
the physiologically relevant pro-BPTI form is still missing.
Leech-derived tryptase inhibitor
Human tryptase b is a trypsin-like serine protease involved
in the pathogenesis of disorders such as asthma and arthritis
(71). Leech-derived tryptase inhibitor (LDTI) is a nonclassical
Kazal-type inhibitor isolated from the medicinal leech Hirudo
medicinalis (14, 72). It is one of two proteins shown to bind
tightly to human tryptase b, making it a molecule of consid-
erable biomedical interest. LDTI comprises 46 residues and
three disulfide bonds (Cys4-Cys29, Cys6-Cys25, and Cys14-
Cys40) (Fig. 2). Its structure, solved both in solution by nu-
clear magnetic resonance (NMR) and in a crystalline complex
with trypsin, shows a short central a-helix and a small triple-
stranded antiparallel b-sheet (41, 56, 73). The first two dis-
ulfides stabilize the a-helix, joining it to the N-terminus of the
protein in a cysteine-stabilized a-helical motif that is widely
found in other bioactive peptides such as endothelins and
toxins from insects and snakes. In the third disulfide, Cys14 in
the b1-strand is linked to Cys40, restricting the mobility of the
b3-strand, and thereby stabilizing the small b-sheet. This
particular topology and disulfide connectivity makes LDTI an
interesting model protein for oxidative folding studies.
The oxidative folding pathway of LDTI has been re-
cently analyzed using acid-trapping, reversed-phase high-
performance liquid chromatography and disulfide-pairing
analysis of its intermediates (3, 59). The folding of LDTI from
the reduced and unfolded state proceeds through a sequential
oxidation of its cysteine residues toward the native confor-
mation. As in the case of BPTI, although 75 different disulfide-
bonded intermediates can be theoretically formed during the
refolding reaction, only 5 of these species accumulate to a
significant extent. First, LDTI oxidizes one of its disulfides to
render 1S intermediates that rapidly reach equilibrium. The
distribution of disulfide bonds in this ensemble significantly
deviates from that expected from simple loop entropy contri-
butions, with a preferential accumulation of the natively
bonded [14–40] species. NMR studies of [14–40] strongly sug-
gest that the characteristic small triple-stranded antiparallel
b-sheet of LDTI is already present in this intermediate. It is
likely that secondary structure propensities promote the
transient formation of the b-sheet approaching Cys14 and
Cys40. The formation of the disulfide bond linking the two
external b-strands would further stabilize the b-sheet. The
structural properties of [14–40] resemble those of [30–51] BPTI
in the sense that the presence of a folded secondary structure
preferentially protects the disulfide bond from reduction and
kinetically favors the prevalence of this intermediate in the 1S
population. Two of the three 2S folding intermediates, des[6–
25] and des[4–29], are generated directly from the oxidation of
two of its free cysteines. The rest of the 1S population re-
arranges and oxidizes its disulfide and free cysteines, respec-
tively, to form the third 2S intermediate: des[14–40]. Therefore,
the three 2S intermediates contain exclusively native disulfide
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bonds. In principle, the oxidation of the two free cysteines in
any of these species would result in the formation of a native
and functional LDTI. However, when the intermediates were
trapped and isolated and their folding was re-initiated at
neutral pH, it became clear that neither des[14–40] nor des[6–
25] can form directly native LDTI but rather reshuffle their
disulfides to form des[4–29], which turns out to be the only
productive intermediate in the folding pathway. The conver-
gence of all 2S intermediates into des[4–29] is due to both the
relative conformational properties of these species and the
different reactivity of their free cysteines. The recently deter-
mined structures of these three 2S intermediates show that
they are highly native (see structural discussion later) (59). In
the des[4–29] structure, Cys29 at the C-terminus of the a-helix
is fully exposed and can react with Cys4 at the highly flexible
N-terminus to produce the native inhibitor. The des[6–25] in-
termediate has a very short half-life and rapidly reshuffles into
des[4–29]. Cys6 has a highly reactive thiolate group. However,
in the structure of the intermediate it is far away from Cys25,
which precludes the direct oxidation reaction. Instead, Cys6
attacks the closer Cys4-Cys29 disulfide bond promoting a fast
reshuffling to form des[4–29]. The oxidative folding of BPTI
illustrated how the formation of a disulfide bond is kinetically
impeded, when, once formed, becomes protected in a stable
and structured conformation. This is likely the reason the
des[14–40] intermediate, similar to des[5–55] and des[30–51] in
BPTI, cannot oxidize directly into the native form and instead
rearranges to form des[4–29]. In contrast to what is observed
for des[6–25], the rearrangement of des[14–40] into the pro-
ductive intermediate is a slow reaction, which promotes the
accumulation of this intermediate during the folding reaction.
Overall, the folding pathway of LDTI is dominated by the
presence of four natively bonded intermediates without sig-
nificant accumulation of scrambled forms. This simplicity in
the conformational space that the protein has to sample to
attain the native structure results in a fast and efficient folding
pathway.
Momordica cochinchinensis trypsin inhibitor II
Momordica cochinchinensis trypsin inhibitor II (MCoTI-II) is
a serine protease inhibitor belonging to the cyclotide sub-
family (22). It comprises 34 residues and three disulfide
bonds, with a structure similar to that of squash protease in-
hibitors, with their cysteine residues displaying a I–IV, II–V,
and III–VI connectivity forming a classical cystine knot motif
(Fig. 2) (42, 49). However, in the case of MCoTI-II the N- and
C-terminus of themolecule are covalently linked resulting in a
cyclic molecule (20). The combination of these two structural
features endows this inhibitor with an exceptionally high
stability. The oxidative folding pathway of MCoTI-II and
other cyclotides has been studied and reviewed by Craik and
coworkers (19, 20). The folding pathway of MCoTI-II is ex-
tremely simple, with a predominant 2S intermediate (des[1–
18]; see structural discussion later) arising from the oxidation
of an initially heterogeneous 1S population. This intermediate
has the two native Cys8-Cys20 and Cys14-Cys26 disulfide
bonds and lacks the Cys1-Cys18 disulfide that is formed by
direct oxidation leading to the native protein. The formation
of the third disulfide bond is the rate-limiting step in the ox-
idative folding reaction. Interestingly, apart from this main
route there is a minor formation of other 2S intermediates that
can also attain the native structure. The energy barrier pre-
cluding the rapid oxidation of the des[1–18] intermediate into
native MCoTI-II is thought to depend on a structural re-
arrangement that would allow orienting the reactive thiols in
the free cysteines in proximity (21). The circular structure of
MCoTI-II strongly reduces the entropy associated with the
unfolded and reduced state of the inhibitor relative to that of
other linear molecules and is likely responsible for the limited
number of conformational states the protein has to sample
before attaining the native structure. Again, as in the cases of
BPTI and LDTI, the presence of a reduced number of natively
bonded intermediates and the absence of scrambled isomers
results in a fast and efficient folding process.
Oxidative Folding via Heterogeneous
Scrambled Isomers
Hirudin
Hirudin is a thrombin-specific protease inhibitor iso-
lated from the medicinal leech H. medicinalis (30). It is a
65-residue protein consisting of two functional domains: a
globular N-terminal domain (NTD) formed by four b-sheets
crosslinked by three disulfide bonds (Cys6-Cys14, Cys16-
Cys28, and Cys22-Cys39) and a disordered negatively
charged C-terminal extension (Fig. 3). The isolated functional
domains possess anticoagulant activity and bind to different
regions of the enzyme: the globular domain docks into the
catalytic site of thrombin, whereas the C-terminal tail interacts
with its fibrinogen binding site (43, 48, 68).
Chatrenet and Chang studied the oxidative folding of
hirudin in the absence and presence of a thiol agent (37). In
contrast to the proteins discussed in the previous section, no
predominant folding pathways or preferentially populated
intermediates were detected. Hirudin appears to fold fol-
lowing a trial-and-error mechanism in which the six cyste-
ines are equally involved in the disulfide reshuffling
reactions that lead to the native state. The main intermedi-
ates that populate the folding process of hirudin are non-
natively bonded 3S species, that is, scrambled isomers. In a
further study the same authors investigated the folding re-
action of the globular domain of hirudin (38). The folding of
this protein can be dissected into two well-differentiated
stages: an initial stage of nonspecific packing and a final step
of consolidation that leads to the native structure. In the first
stage, reduced and unfolded hirudin oxidizes its free cyste-
ines to sequentially form equilibrated populations of 1S, 2S,
and 3S (scrambled) intermediates. All these ensembles are
highly heterogeneous and there is no apparent contribution
of noncovalent interactions to the intermediate distribution.
Of a total of 60 potential 1S and 2S species, at least 30 ac-
cumulate in the reaction, and 11 of the 14 theoretically pos-
sible scrambled isomers could be detected (36). This finding
suggests that the driving force at this initial folding stage is
an unspecific hydrophobic collapse to attain a compact
conformation through a nearly random disulfide pairing.
Scrambled hirudin forms are more compact than 1S or 2S
intermediates, but they do not possess a unique restricted
conformation and accordingly, in contrast to native hirudin,
are highly sensitive to proteolytic attack. During the last
stage of folding this heterogeneous population of scrambled
intermediates reshuffles its disulfide bonds to attain na-
tive disulfide connectivity. The consolidation of scrambled
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species is highly enhanced by the presence of a thiol catalyst;
in the scrambled isomers all cysteines are involved in the
formation of disulfide bonds, so there are no free thiolates to
behave as catalysts in the reshuffling reaction. Therefore,
scrambled isomers act as kinetic traps, their consolidation
being the rate-limiting step in the folding reaction. In con-
trast to what was previously assumed, in the case of hirudin
scrambled isomers are on-pathway intermediates and not
dead-end species. The establishment of specific noncovalent
interactions guides the attainment of the native structure
from scrambled isomers, but these native-like contacts do
not occur through a preferential pathway, which makes the
overall process extremely slow and inefficient in comparison
with that of BPTI-like proteins.
Potato carboxypeptidase inhibitor
Potato carboxypeptidase inhibitor (PCI) is a 39-residue
globular protein that strongly inhibits metallocarbox-
ypeptidases (64, 67). This small protein is part of the defense
system of the potato plant against insect attack. Its structure is
known both in solution (45) and in a crystalline complex with
bovine carboxypeptidase A (64). It consists of a 27-residue
core, stabilized by the presence of three disulfide bonds (Fig.
3). Cys8-Cys24 andCys12-Cys17 form a nine-residue ring that
Cys18-Cys34 is positioned through, resulting in a classical
T-knot motif. From this central core protrude a seven-residue
N-terminal and a five-residue C-terminal tail, the latter being
the primary binding site of PCI to the enzyme.
In contrast to hirudin, PCI lacks secondary structure el-
ements, except for a short 310 helix and a very small b-sheet.
However, mechanistically, the oxidative folding pathways
of these two proteins are nearly indistinguishable (9, 34, 76).
As for hirudin, the folding of PCI shows an initial step of
nonspecific disulfide pairing characterized by a flow from
the reduced=unfolded form to scrambled isomers through
the sequential formation of highly heterogeneous 1S and 2S
populations. This process is not guided by noncovalent in-
teractions since the presence of denaturants does not alter
the distribution and=or flow of the different species that
accumulate. Subsequently, scrambled isomers reshuffle their
disulfide bonds to produce the native inhibitor. Again, from
a kinetic point of view, the process of consolidation repre-
sents the rate-limiting step in the folding reaction. The oxi-
dative folding of PCI is an extremely inefficient process,
being about 10 times slower than that of hirudin. The ab-
sence of a predominant secondary structure that could ef-
ficiently drive the reaction toward a global minimum
and=or the high energy barrier associated with the exposure
of hydrophobic residues (partially hidden in the core of
scrambled PCI forms) necessary to attain the native fold
might account for this behavior.
FIG. 3. Oxidative folding of hirudin-like proteins. The amino acid sequence, secondary structure elements, and disulfide
pairings of hirudin (3 SS and 51 residues), PCI (3 SS and 39 residues), and tick anticoagulant peptide (TAP; 3 SS and 60
residues) are schematically shown. The Protein Data Bank ID codes for the structures of hirudin, PCI, and TAP are, re-
spectively, 3HTC, 1TAP, and 1H20 (ribbon plots prepared with program PyMOL). The C-terminal domain (CTD) of hirudin
(residues 50–65) has a disordered structure and is not shown here. The disulfide bonds are shown as black sticks. An
overview of the oxidative folding pathway of hirudin, PCI, and TAP is shown below each sequence. The nomenclature of the
different species is described in the legend of Figure 2.
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Similar to BPTI, PCI is synthesized in vivo as a precursor
protein that includes a 27-residue N-terminal and a seven-
residue C-terminal pro-region. Comparison of the oxidative
folding of mature PCI and PCI containing the N-terminal pro-
sequence indicated that this molecule does not depend on
this pro-region for its folding in vitro, or in vivo in Escherichia
coli (18).
Tick anticoagulant peptide
Tick anticoagulant peptide (TAP) is a small serine protease
inhibitor purified from extracts of the soft tick Ornithodoros
moubata (77). This 60-residue protein is a slow tight-binding
inhibitor specific for the blood coagulation factor Xa. Its
structure was solved in solution by NMR (1, 53). Importantly,
TAP was shown to be a Kunitz-type inhibitor, with an overall
conformation closely related to that of BPTI, that is, consisting
of a double-stranded antiparallel b-sheet, an a-helix, and a
small hydrophobic core. In addition, BPTI and TAP share
the same disulfide connectivity, with TAP’s Cys5-Cys59,
Cys15-Cys39, and Cys33-Cys55 disulfides being structurally
homologous to BPTI’s Cys5-Cys55, Cys14-Cys38, and Cys30-
Cys51 disulfides, respectively. Therefore, in principle, one
should expect that the oxidative folding of TAP would pro-
ceed efficiently through a preferential route displaying a
limited number of stable, native-like intermediates. Instead,
reduced and unfolded TAP acquires its native structure fol-
lowing a pathway that is, in many aspects, indistinguishable
from that of hirudin and PCI (Fig. 3). Ten of 15 theoretically
possible 1S isomers were detected by Chang and coworkers at
the initial folding steps (31), indicating a quasi-random for-
mation of the first disulfide and, in contrast to what happens
with BPTI, the absence of selective noncovalent contacts that
can structurally and kinetically promote the accumulation of a
preferential 1S intermediate. The species in the equilibrated 1S
population oxidize two of their free cysteines to render a
heterogeneous 2S ensemble in which, again, no structural bias
is observed. Upon equilibration the 2S intermediates form the
last disulfide to produce scrambled isomers that become
trapped in the absence of thiol catalysts. Although the
scrambled ensemble is still heterogeneous, 4 of the 14 possible
3S isomers represent about 70% of the population. This re-
duction in the heterogeneity of the conformational space is not
the result of the establishment of selective contacts between
side chains, but rather of an unspecific hydrophobic collapse,
since a common feature of these major scrambled isomers is
that none contain native disulfides, and in all cases the de-
tected disulfide connectivity is incompatible with the pres-
ence of a native double-stranded b-sheet. As for hirudin and
PCI, the last stage in the oxidative folding of TAP is the con-
solidation of the scrambled isomers to acquire the native
conformation. For TAP, all major scrambled forms are able to
convert into the native protein at the end of the reaction, but
before attaining this conformation they equilibrate with the
other scrambled forms. Isolated scrambled forms equilibrate
faster with other scrambled species sharing a common dis-
ulfide bond, because such conversions imply reorganization
of only two pairs of disulfides.
The heterogeneity of folding intermediates, the sequential
flow from the reduced and unfolded protein through oxida-
tion of disulfides, and the inefficiency of the last stage of
folding in the absence of thiol catalysts due to the large ac-
cumulation of scrambled isomers are characteristics reminis-
cent of those exhibited by hirudin and PCI. However, there is
one important difference concerning the stability and con-
formation of the intermediates in the folding pathway. In the
case of TAP, all three classes of intermediates, that is, 1S, 2S,
and 3S, contain species that are susceptible to denaturant,
suggesting that their structures are locally stabilized by non-
covalent interactions. Although the free energy associated
with these species is likely to be marginal, especially for 1S
and 2S, overall they act as kinetic traps that slow down the
transition toward the subsequent equilibrated population. In
the presence of a denaturing agent that disrupts these con-
tacts, the speed and efficiency of the folding reaction are sig-
nificantly increased. These results suggest that the presence of
stable intermediates does not necessarily facilitate folding;
they can impede kinetically the flow of intermediates and
delay the attainment of the functional fold (35).
Oxidative Folding via Native and Scrambled Isomers
BPTI- and hirudin-like proteins exemplify two opposite
oxidative folding landscapes. As illustrated by the cases of
BPTI and TAP, the oxidative folding of a protein is not
determined exclusively by its global protein conformation
and=or disulfide connectivity. Although the folding behavior
of both types of proteins should be somehow encoded in the
primary polypeptide sequence, it is still not possible to deci-
pher how this linear information determines the complex
route that a small disulfide-rich protein has to follow to gain
its unique functional structure. Thus, the study of protein
models displaying mixed pathways in which both native and
scrambled intermediates accumulate is of much interest to
provide insight into the mechanisms of oxidative folding.
Leech carboxypeptidase inhibitor
Leech carboxypeptidase inhibitor (LCI) is a 67-residue
metallocarboxypeptidase inhibitor found in the medicinal
leechH. medicinalis (66). Interestingly, it is a potent inhibitor of
plasma carboxypeptidase B, also known as thrombin-activa-
table fibrinolysis inhibitor, which is an emerging biomedical
target for thrombolysis and thrombolytic therapies. The
structure of LCI was solved both in solution and in a crys-
talline complex with human carboxypeptidase A2 (65). LCI
folds in a compact domain comprising a five-stranded anti-
parallel b-sheet with a b3-b1-b2-b5-b4 topology and a short a-
helix that packs onto the most compact part of the b-structure
(Fig. 4). The native conformation of the inhibitor is highly
stabilized by the occurrence of four disulfide bonds, Cys11-
Cys34, Cys18-Cys62, Cys19-Cys43, and Cys22-Cys58, all of
them located within regular secondary structure elements.
The disordered C-terminal tail of LCI is the primary binding
site of the enzyme, as previously described for PCI.
LCI displays a higher extent of secondary structure than its
three-disulfide protease inhibitor counterparts, which affects
the accessibility, proximity, and reactivity of the thiols and
disulfide bonds. In addition, the presence of two additional
cysteine residues increases almost 10-fold the number of in-
termediates that could potentially arise during the oxidative
folding reaction. The combination of these two factors results
in a rather complex folding landscape (4, 69). The folding of
LCI proceeds initially through a heterogeneous formation of
1S and 2S intermediates. The presence of moderate amounts
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of denaturing agents does not alter the number or relative
abundance of 1S and 2S species, suggesting that their distri-
bution at equilibriumdoes not respond to the establishment of
specific side chain contacts, but rather to entropy constraints.
This is in good agreement with computational predictions,
suggesting that 1S and 2S LCI species do not contain an ex-
tensive regular structure (6). This heterogeneity is strongly
reduced in the 3S population, which was initially thought to
consist exclusively of two intermediates displaying native
disulfide connectivity: des[19–43] and des[22–58]. Because no
other 3S forms were detected it was assumed that these two
native-like species could originate directly from the oxidation
of the third disulfide bond in the 2S ensemble. However, the
lack of an enthalpic bias toward the formation of native dis-
ulfides in 2S implies that only a minor fraction of the isomers
in this ensemble would display a native combination of dis-
ulfide bonds, making the direct and preferential formation of
natively bonded 3S species a very improbable reaction. In a
recent study, the contribution of each particular disulfide to
the folding of LCI was investigated by constructing a series of
single and multiple mutants lacking one to four disulfide
bonds (6). This work allowed reformulating the folding
pathway of this protein, specifically the formation, distribu-
tion, and role of 3S isomers in the folding reaction. The results
demonstrated that in LCI 3S isomers can be effectively formed
in the absence of the fourth disulfide bond and, more im-
portantly, that these wrongly bonded species can rearrange
their disulfides to render 3S forms with native disulfides and
native-like conformations. Therefore, a more plausible
mechanism for the formation of des[19–43] and des[22–58]
intermediates would be the nonspecific oxidation of the
unfolded 2S ensemble to 3S species and the subsequent re-
shuffling of these forms into these two predominant inter-
mediates. Thus, the initial stages of LCI folding comprise a
quasi-stochastic consolidation of the protein, and resemble
those of hirudin. Nevertheless, des[19–43] and des[22–58]
intermediates are reminiscent of the intermediates present in
the oxidative folding of BPTI, in the sense that in contrast to
the other 3S species, they have a highly folded structure. This
endows themwith the highest stability in the ensemble, and at
the same time protects their native disulfide bonds from re-
duction and=or reshuffling, which kinetically favors the large
accumulation of these species in the 3S ensemble (7, 11). The
high stability and low reactivity of des[19–43] and des[22–58]
cause them to act as strong kinetic traps that freeze the reac-
tion at the 3S stage. Consequently, the destabilization of such
intermediates by denaturing agents allows the progress of the
pathway and accelerates the recovery of native protein. In
principle, the direct oxidation of the free thiolates in any of
these intermediates would promote the formation of the na-
tive inhibitor. The formation of the native conformation is
thermodynamically favored, since it is at least two times more
stable than any of the intermediates. However, in contrast to
what happens with BPTI and LDTI, the free thiolates are not
in flexible and exposed loops but shielded by the secondary
structure elements (see structural discussion later), as dem-
onstrated by their inability to react with external thiols. This
hidden location of the free cysteines in the intermediates has
a dramatic effect on the progress of the folding reaction be-
cause structural fluctuations expose both the thiols and the
disulfide bonds, thus promoting their reshuffling instead of
the oxidation of free thiols into the native disulfide pairing.
Therefore, the gained native structure becomes lost and a
population of compact but unstructured 4S scrambled iso-
mers subsequently accumulates. As for hirudin and PCI, the
reshuffling of these disulfide-blocked species is very slow in
the absence of an external thiol catalyst. The reorganization of
the misconnected disulfide bonds to finally attain the native
form becomes the major rate-limiting step in the LCI folding
reaction. In the folding pathway of LCI both scrambled and
native intermediates are necessary to attain a unique stable
conformation. In addition, in contrast to general assumptions,
scrambled but not native-like intermediates are the produc-
tive species. LCI illustrates how the search for the conforma-
tional stability and reduced flexibility that provide the native
disulfide connectivity complicates the folding reaction and
makes it extremely inefficient, suggesting that the conforma-
tional space that small disulfide-rich proteins have to explore
to attain the functional form is shaped primarily in thermo-
dynamic terms.
Oxidative Folding of Two-Domain Protease Inhibitors
Approximately 75%of eukaryotic protein sequences fold into
conformations consisting of more than one domain (15). How-
ever, information about the mechanisms driving the folding
of two-domain proteins is still scarce. This is mainly due to
the limitation of indirect structural probes such as intrinsic
FIG. 4. Oxidative folding of leech carboxypeptidase inhibitor (LCI). The amino acid sequence of LCI (4 SS and 67
residues), as well as its secondary structure elements and disulfide pairings, is schematically shown. The Protein Data Bank
ID code for the structure is 1DTV (ribbon plot prepared with program PyMOL). The disulfide bonds are shown as black
sticks. An overview of the oxidative folding pathway of LCI is shown at the bottom. The nomenclature of the different species
is described in the legend of Figure 2.
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fluorescence or ellipticity to monitor folding=unfolding transi-
tions in two-domain proteins where the two protein moieties
can fold=unfold autonomously or in a cooperative way. During
oxidative folding the formation of disulfide bonds acts as a
covalent structural probe, providing unbiased information
about the proximity of the different regions of the polypeptide
chain. Therefore, studies of multidomain proteins in which the
different moieties are stabilized by disulfide bonds might allow
characterization of the extent to which the folding reactions of
this kind of polypeptide relies on the establishment of inter-
domain interactions. Recent studies on the oxidative folding of
two-domain protease inhibitors have provided valuable in-
sights into the complicated folding landscape that multidomain
proteins must face before attaining their native conformation.
Ascaris carboxypeptidase inhibitor
The metallocarboxypeptidase inhibitor Ascaris carboxy-
peptidase inhibitor (ACI) isolated from Ascaris, the most
common human parasite of the gastrointestinal tract that
causes the pandemic disease ascariasis, is 67 residues long and
contains five disulfide bonds (70). The crystal structure of ACI
in complex with human carboxypeptidase A1 reveals two
structurally similar tandemmodules (Fig. 5), anNTD and a C-
terminal domain (CTD), which are linked by a connecting
segment (CS). Each domain comprises a small helix and a C-
terminal b-sheet that are stabilized by two disulfide bonds
(Cys6-Cys18, Cys12-Cys25; and Cys43-Cys58, Cys49-Cys63).
The CS includes an a-helix, which is linked to the b-sheet of
the CTD by the Cys34-Cys62 disulfide bond.
The oxidative folding of ACI has been recently examined,
showing that this protein folds through the sequential for-
mation of 1S, 2S, 3S, and 4S intermediates that subsequently
evolve into amixture of 5S (scrambled) isomers (13). Similar to
the cases of hirudin, PCI, TAP, and LCI, the reshuffling of this
heterogeneous population of scrambled isomers into the na-
tive protein represents the rate-limiting step of the folding
reaction and is efficiently promoted by the presence of thiol
FIG. 5. Oxidative folding of two-domain protease inhibitors. The amino acid sequence, secondary structure elements, and
disulfide pairings of Ascaris carboxypeptidase inhibitor (ACI; 5 SS and 67 residues), tick carboxypeptidase inhibitor (TCI; 6 SS
and 75 residues), and secretory leukocyte protease inhibitor (SLPI; 8 SS and 107 residues) are schematically shown. The
Protein Data Bank ID codes for the structures of ACI and TCI are, respectively, 3FJU and 2JTO (ribbon plots prepared with
program PyMOL). The disulfide bonds are shown as black sticks. The N-terminal domain (NTD) and CTD and the con-
necting segment (CS) are indicated. An overview of the oxidative folding pathway of ACI, TCI, and SLPI is shown below
each sequence. The nomenclature of the different species is described in the legend of Figure 2.
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catalysts. However, the presence of redox agents does not
prevent the final accumulation of a major scrambled isomer,
which elutes very close to native ACI in the reversed-phase
chromatogram. This scrambled species could arise from
the presence of two consecutive cysteines located at the C-
terminus of ACI, which could easily lead to divergent dis-
ulfide pairings (see also Tick carboxypeptidase inhibitor section).
This nonproductive species is not expected to accumulate in
vivo since the presence of protein disulfide isomerase, which
catalyzes the formation and isomerization of disulfide bonds
in the eukaryotic endoplasmic reticulum, efficiently prevents
its formation. The folding analysis of truncated ACI variants
lacking the NTD or both the NTD and CS revealed that the
NTD has an influence on the folding of the CTD, so that the
two domains of ACI do not fold autonomously, but rather
cooperatively. It appears that the NTD assists in the folding of
the CTD, most likely through transient interdomain disulfide
interactions, acting as a kind of intramolecular chaperone.
This result provides a plausible explanation for the two-
domain architecture of this molecule, since the NTD does not
contribute significantly to the inhibition of target enzymes.
Tick carboxypeptidase inhibitor
Tick carboxypeptidase inhibitor (TCI) is a protein of 75
residues and six disulfide bonds isolated from the hard tick
Riphicephalus bursa (8). Like LCI, it is a tight binding inhibitor
of thrombin-activatable fibrinolysis inhibitor able to stimulate
the fibrinolysis of blood clots and thus constituting a prom-
ising molecule for thrombolytic therapies (8). The crystal
structure of TCI in complex with different metallocarbox-
ypeptidases revealed that it consists of two domains that
are structurally similar and contribute to the inhibition of the
enzyme in a double-headed manner (12). Each domain
consists of a short a-helix followed by a small twisted anti-
parallel b-sheet, a motif structurally homologous to that of
b-defensin-like proteins (Fig. 5). The solution structure of TCI
has recently shown that these two rigid globular domains are
joined by a flexible linker (60). Each domain is strongly con-
strained by the presence of three disulfide bonds with iden-
tical I–V, II–IV, and III–VI connectivity.
The oxidative folding of TCI from the reduced and un-
folded protein to the native state proceeds through a se-
quential oxidation of cysteine residues, which is characterized
by the presence of intermediates displaying one to six dis-
ulfide bonds (5). The overall mechanism recalls that of the
single-domain LCI, because both scrambled and natively
bonded species are obligatory intermediates in the folding
pathway. The presence of 12 free cysteines implies a large
number of possible intermediates. Indeed, numerous species
are found in the 1S and 2S population, without any detectable
enthalpic bias. However, the equilibrated 3S ensemble is
clearly dominated by the accumulation of only two folding
intermediates that comprise three native disulfide bonds in
one domain and no disulfide bonds in the other: [3–31, 10–27,
16–32] and [40–70, 47–64, 54–71]. Importantly, nonnative 3S
species could not be detected, indicating that they either do
not form or, more likely, are kinetically unstable relative to the
natively connected folding intermediates. The structures of
the 3S isolated intermediates support this view (see structural
discussion later), because in both cases the disulfide-linked
domain displays a stable native-like conformation, which
protects disulfides from reduction and reshuffling (10). Ac-
cording to the TCI structure any other combination of dis-
ulfides would result in at least one of the bonds being
accessible to solvent and therefore potentially reactive. The
folding reaction proceeds through a sequential oxidation of
the free thiols in the intermediates to finally render an equil-
ibrated population of 6S scrambled isomers. The folding of
TCI finds difficulty reaching completion in the absence of thiol
catalysts, and only 15% of the protein attains the native con-
formation, even after 2 days of refolding. The reshuffling re-
action is exceedingly slow and therefore constitutes the major
rate-limiting step of the folding pathway. Similar to ACI, even
in the presence of redox agents there is a final accumulation of
a stable scrambled isomer that elutes closely to native TCI.
Again, this nonproductive species is avoided by the addition
of protein disulfide isomerase to the folding reaction mixture.
The oxidative folding of TCI comprises the accumulation of
many disulfide intermediates. In principle, this complexity
could arise from the formation of nonnative interdomain
disulfide bonds. Nevertheless, this type of disulfide could not
be detected, suggesting that the two domains fold autono-
mously without any extensive interaction between both pro-
tein moieties. This lack of cooperation between the two
domains occurs already at the early stages of folding that lead
to the formation of the twomajor 3S intermediates. This fact is
evidenced by the ability of individual TCI domains to acquire
a native disulfide pairing from their respective reduced and
unfolded states. Importantly, despite their homologous
structures and identical disulfide connectivity, the two do-
mains of TCI fold at very different rates and through dis-
tinct mechanisms. The CTD folds rapidly through a limited
number of intermediates, whereas in the case of the NTD the
reaction is slower and the intermediates are far more hetero-
geneous. In both TCI domains the formation of scrambled
isomers precedes and hinders the acquisition of native dis-
ulfide connectivity. The formation of two different 3S inter-
mediates in which only one domain is folded is an exceptional
property of TCI. Usually, when the different moieties of a
multidomain protein fold autonomously, only the thermo-
dynamicallymost stable or kineticallymost favored domain is
able to acquire a native structure before the other domains can
fold. In TCI the twomajor 3S intermediates can independently
evolve through sequential oxidation to produce the native
protein. Overall, the folding of TCI results from the sum of the
folding pathways of its individual domains and exhibits a
previously unreported symmetry in which, independent of
the domain that folds first, the second can fold in a nonco-
operative manner to render the functional inhibitor. The
sequential and autonomous folding of two 3S domains
clearly implies a much less complex conformational search
than that associated with the cooperative formation of six
disulfide bonds, in which case >10,000 possible 6S isomers
are possible.
Secretory leukocyte protease inhibitor
Secretory leukocyte protease inhibitor (SLPI), also named
mucous proteinase inhibitor, is a 107-residue serine protease
inhibitor found in humanmucous fluids (74). Its physiological
function seems to be the protection of the mucosal epider-
mis against degradation by proteases, especially those con-
tained in granulocytic lysosomes, which suggests a possible
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therapeutic use against local inflammatory processes. The
crystal structure of SLPI in complex with a-chymotrypsin
shows that the inhibitor folds in two independent domains in
a boomerang-like structure (Fig. 5) (47). The C-terminal se-
quence of each domain organizes into two b-strands linked by
a hairpin turn, whereas the N-terminal part consists of a loop
covalently linked to the b-sheet, which constitutes the primary
binding site of the protease. Each domain is stabilized by the
presence of four disulfide bonds with I–VI, II–VII, III–V, and
IV–VIII connectivity.
The presence of 16 free cysteine residues in the reduced
and unfolded state of SLPI could result in an extremely
complex oxidative folding reaction for this inhibitor. More
than 40 million different species could accumulate along
the pathway, with 2 million corresponding to 8S scrambled
isomers; that is, the folding reaction would be exceedingly
inefficient. Lin and Chang analyzed the oxidative folding of
SLPI, finding that, surprisingly, despite the complicated
theoretical folding landscape of SLPI, this protein folds
very efficiently into the two-domain native architecture
without requiring a thiol catalyst (54). This property is
unique and intriguing in light of the SLPI native structure,
which lacks an extensive regular structure that could drive
a coupled conformational and oxidative folding reaction.
Even in the case that the protein adopts a folding pathway
in which only native disulfide bonds are formed, 254 dif-
ferent species would populate the pathway. Moreover, the
folding pathway of SLPI comprises a highly heterogeneous
population of folding intermediates that includes scram-
bled isomers, which discredits the idea that folding occurs
through a BPTI-like mechanism. In fact, the folding of SLPI
follows a two-stage mechanism that combines features of
both BPTI- and hirudin-like proteins. During the first stage
of folding, reduced and unfolded SLPI sequentially oxi-
dizes its disulfide bonds to form a highly heterogeneous
mixture of intermediates that finally converges in the for-
mation of 6S and 7S isomers comprising nonnatively and
natively bonded intermediates. The main 6S intermediate is
des[18–43, 71–97], which contains the three cysteines lo-
cated in the b-strands of each domain correctly bonded,
forming I–VI, III–V, and IV–VIII disulfide bonds, and lacks
the II–VII bond joining the protease binding loops in both
domains. The main 7S intermediate corresponds to des[18–
43], which lacks the II–VII bond in the first domain. Pre-
sumably both intermediates display a partially folded
conformation, which protects preferentially the linked dis-
ulfides promoting its accumulation and its role as a kinetic
trap in the flow of the reaction. In the second stage of
folding, des[18–43, 71–97] converts into des[18–43] through
direct oxidation of its Cys71 and Cys97 residues, and the
newly formed and previously accumulated des[18–43] ox-
idizes into the native SLPI. Similar to BPTI, these reactions
are favored by the presence of free cysteines in flexible and
exposed loops. This is likely the reason that they can act as
thiol catalysts, facilitating the reshuffling of the remaining
nonnatively bonded isomers toward native pairings that
further evolve into native intermediates and finally form
the functional inhibitor. It also explains why SLPI folds
efficiently in the absence of external redox agents. There-
fore, in contrast to TCI and more similar to ACI, the folding
of SLPI comprises interdomain interactions and is a coop-
erative reaction.
Structures of Protease Inhibitors’
Folding Intermediates
The paradigmatic cases of BPTI and TAP illustrate how the
native nature and heterogeneity of the different intermediates
that populate the folding pathway of a given protein cannot be
directly inferred from its native structure and=or disulfide-
bond connectivity. This situation is in contrast to the case of
proteins folding via a two-state mechanism, which constitute
the other major benchmark for the characterization of folding
reactions. In two-state folders, the mere topology of the native
state determines the overall protein folding rate and the
placement of transition states in the pathway (61), in such a
way that proteins featuring primarily local contacts tend to fold
more rapidly and exhibit less compact folding transition states
than those displaying more nonlocal interactions. This rule
does not apply to oxidative folding because conformational
folding is obligatorily coupled to disulfide-bond formation.
This means that the establishment of nonnative local contacts
can be forced by nonnative disulfide pairings or, on the other
hand, that native local contacts and secondary=tertiary struc-
ture formation can be strongly accelerated by the formation of
native covalent links. At the same time, the progress of con-
formational folding influences the proximity, accessibility, and
reactivity of free thiols and disulfide bonds. This makes the
prediction of folding pathways in small disulfide-rich proteins
a daunting task. Overall, the complex process of oxidative
folding appears to depend on the specific conformational
properties of the intermediates that accumulate in the reaction,
rather than in the entropically and enthalpically stabilized final
conformation. Therefore, the structural characterization of
disulfide folding intermediates is becoming a central issue in
oxidative folding. So far such structural studies have largely
focused on analogs where one or more disulfide bonds were
chemically blocked or deleted by mutation of cysteines to ala-
nines or serines, for example, in the special cases of BPTI or
RNase A (2). However, chemically inert analogs suffer from
steric strain and repulsion due to the volume and net charge of
the blocking reagents, and genetically engineered analogs have
been shown to differ frequently in stability and conformation
from the corresponding genuine intermediates (6). In the last
five years, seven genuine intermediates isolated directly from
folding=unfolding reactions have been structurally character-
ized in acidic solution (i.e., conditions where they are stable) by
NMR spectrometry (Fig. 6). Notably, all of them correspond to
protease inhibitor models: one intermediate from LCI, one
from MCoTI-II, two from TCI, and three from LDTI (7, 10, 21,
59). These intermediates are des species lacking from one to
three disulfide bonds, but in all cases the already-formed dis-
ulfides display native connectivity.
From a general point of view, oxidative folding interme-
diates lacking a single disulfide bond can be classified as
productive or nonproductive species, where productive in-
termediates are those that can directly oxidize their free thiols
to render the native and functional protein. As proposed by
Scheraga and coworkers, they can be also classified as ‘‘dis-
ulfide-secure’’ or ‘‘disulfide-insecure’’ intermediates accord-
ing to the reactivity of the already formed native disulfide
bonds (57, 81). Nonproductive intermediates tend to be dis-
ulfide-insecure; they are normally long-lived, native-like,
stable forms that act as strong kinetic traps during oxidative
folding reactions. The solution structure of des[22–58] LCI
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shows the molecular determinants responsible for such be-
havior (7). This intermediate possesses a well-defined globu-
lar conformation that closely resembles that of the native
inhibitor, including a four-stranded antiparallel (b3-b1-b2-b5)
b-sheet, although certain regions are more disordered than in
the native state and the a-helix is not properly formed. Despite
the increased flexibility and lower compactness of the inter-
mediate, proton=deuterium exchange experiments demon-
strated that both free cysteines (Cys22 and Cys58) and the
three native disulfide bonds are located in protected regions
and have limited accessibility. This restricted exposure to
solvent is also evident from the fact that both free thiols and
disulfide bonds are insensitive to the presence of external thiol
agents. The burial of the free thiol groups inside a native-like
structure would hinder any further progress in the folding
reaction. However, the increased overall flexibility of the
backbone promotes structural fluctuations that allow the in-
termediate to escape from this trap. Because of their similar
degrees of protection, fluctuations that expose the free thiols
also expose the disulfide bonds, resulting in disulfide re-
shuffling into 4S scrambled forms instead of direct oxidation
of the missing disulfide bond into the native structure. In
des[22–58] LCI reshuffling can compete effectively with oxi-
dation due to the conformational similarity between a re-
shuffling reaction and the second step of an oxidation reaction
(81).
In contrast to des[22–58] LCI, the des[1–18] intermediate of
MCoTI-II is a productive species able to directly render the
native inhibitor by direct oxidation of its free thiols. The so-
lution structure of this intermediate shows that it displays
native secondary and tertiary structure, the only exception
being a flexible loop, the movement of which in the native
state is restricted by the Cys1–Cys18 disulfide bond, forcing
its collapse against the protein core. The absence of the co-
valent link in the intermediate results in a loop more loosely
associated with the rest of the protein (21). However, proton=
deuterium exchange experiments demonstrated that the
number of slowly exchanging amide protons in the interme-
diate is comparable to that of the native protein, indicating
that both forms display similar rigidity. The rigidity in the
overall scaffold of des[1–18]MCoTI-II turns it into a disulfide-
secure intermediate in which structural fluctuations prefer-
entially change the environment of their thiol groups while
keeping their disulfide bonds in a protected native location.
FIG. 6. Solution structures of major folding intermediates. Ca-structure representation of the average structures of LCI,
MCoTI-II, TCI, and LDTI (native forms), together with those of their major folding intermediates—missing the disulfide
bonds shown between parentheses (figure prepared with program PyMOL). The Protein Data Bank ID codes are as follows:
LCI (1ZFI), des[22–58] (1ZFL), MCoTI-II (1IB9), des[1–18] (2PO8), TCI (2K2X), des[CTD] (2K2Y), des[NTD] (2K2Z), LDTI
(2KMO), des[4–29] (2KMP), des[6–25] (2KMQ), and des[14–40] (2KMR). For clarity, the molecules are in the same orientation
as their ribbon plot structures in Figures 2, 4, and 5. Regions with increased flexibility are indicated by arrows. Dashed lines
represent the unfolded and unpaired domains of TCI intermediates.
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This is reflected by the surface accessibilities of the two free
cysteines in the intermediate, which are much larger than
those in the native state, where they become part of the hy-
drophobic core. Molecular dynamic simulations suggest that
in the absence of the disulfide bond the rigid native confor-
mation is thermodynamically destabilized with respect to the
more flexible intermediate structure. Therefore, although the
free cysteines are ready for oxidation and do not competewith
the disulfide bonds, the fact that the protein backbone must
adopt an energetically unfavorable conformation before both
cysteines can oxidize slows down significantly the productive
formation of the native form.
The two main 3S folding intermediates of the two-domain
inhibitor TCI illustrate how the preferential burial of native
disulfide bonds into a compact native structure protects them
from reshuffling reactions that could be initiated by reactive
free cysteines. As discussed above, each intermediate com-
prises three native disulfide bonds in one domain and no
disulfide bonds in the other. This means that each interme-
diate has six free thiols that can potentially initiate a disulfide
exchange reaction with the preformed disulfide bonds.
Moreover, the solution structures of these two intermediates
indicate that these free cysteines are found in a disordered and
highly flexible context, which in principle would strongly
favor the disulfide attack (10). However, this type of reaction
does not occur and the already formed covalent bonds remain
intact in both intermediates during the rest of the folding re-
action. The reason for this protection is that the structures of
the folded NTD and CTD in the intermediates are exactly the
same as the corresponding ones in the native inhibitor, with
all the disulfide bonds highly buried and protected from
solvent in a globular and highly compact conformation.
Therefore, the folding pathway proceedswith the oxidation of
the free cysteines in the unfolded domain.
LDTI is the first protein model for which all the genuine
des species preceding the formation of the native structure
have been structurally characterized (59). As discussed
above, they consist of three intermediates each containing
two native disulfide bonds and a pair of free thiols: des[4–
29], des[6–25], and des[14–40]. Among these species only
des[4–29] is a productive intermediate that yields the native
inhibitor by direct oxidation of its free thiols. The other two
intermediates reorganize their disulfide bonds to converge
in the productive intermediate. LDTI shows a reduced
amount of secondary structure, that is, a short a-helix and a
small triple-stranded antiparallel b-sheet in a b2-b1-b3 to-
pology. Despite the overall packing of LDTI, which was
thought to rely on the special Kazal-type connectivity of its
disulfide bonds, the three des intermediates display essen-
tially the same fold and secondary structure motifs as native
LDTI, except des[14–40], which lacks the b3-strand due to
the missing disulfide. Importantly, the nonproductive
des[6–25] and the productive des[4–29] intermediates posses
a well-packed and structurally identical core, with a rms-
deviation of only 1.3A˚, the main difference between them
being a more flexible N-terminus in des[4–29]. In contrast to
LCI, in LDTI these productive and nonproductive interme-
diates display almost identically accessible free thiols and
disulfide bonds. In both intermediates the Cys14–Cys40
disulfide is buried in the native b-sheet, whereas the other
disulfide connecting the a-helix to the N-terminal loop and
the free thiols are fully accessible. This indicates that the
productivity of a folding intermediate depends on more
subtle structural determinants than the mere exposure of its
free or bonded cysteine residues. In fact, the balance be-
tween reshuffling and oxidation depends on the accessibil-
ity, but also on the proximity and reactivity, of the groups
involved. In des[6–25] the two latter factors shift the balance
toward reshuffling into des[4–29] rather than toward the
formation of the native inhibitor via oxidation. Cys25 is lo-
cated at the N-terminus of the a-helix where a partial pos-
itive charge of the dipole stabilizes the thiolate, lowering the
effective pKa of this group and making it highly reactive.
The flexibility of the backbone in the intermediate brings
this reactive cysteine close to the accessible Cys4–Cys29
disulfide bond instead of to the free Cys6, which results in
disulfide exchange instead of oxidation. Together, the
structures of the LDTI folding intermediates suggest that the
accessibility of the free thiols ensures that an intermediate is
a disulfide-secure, productive species only if all the native
disulfide bonds are fully buried and cannot be attacked by
the free thiols.
Concluding Remarks
Protease inhibitors comprise an extremely large number of
molecules with different sequential and structural character-
istics. They are usually small proteins crosslinked by several
disulfides, which have turned them into outstanding models
for the study of the complex process of oxidative folding.
Although only two classes of protease inhibitors have been
studied to date, namely, serine and metalloprotease inhibi-
tors, a surprisingly high diversity of folding scenarios have
been detected. Expanding folding studies toward the unex-
plored cysteine and aspartic protease inhibitors would likely
uncover new folding processes. Unfortunately, it is still not
possible to forecast the folding landscapes that small dis-
ulfide-rich proteins have to face by using only the confor-
mation and covalent connectivity of their native structures.
The aforementioned structures of genuine folding interme-
diates are providing the first clues to the molecular determi-
nants that guide the last stages of oxidative folding. However,
structural information is still scarce regarding the initial
folding steps preceding the formation of stable intermediates.
In the forthcoming years research should be focused on
these fast and intricate but crucial events. The use of well-
established approaches for the study of fast-folding proteins
will be of much help. Understanding the general rules that
govern oxidative folding at different stages would provide a
unique opportunity to attract theoretical groups to this re-
search area and guide the development of bioinformatics
approaches to assist in the prediction and design of the fold-
ing pathways of small disulfide-rich proteins. What becomes
obvious is that protease inhibitors will, in the years to come,
provide one of the main bedrocks from which to understand
the complexity of oxidative folding.
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ACI¼Ascaris carboxypeptidase inhibitor
BPTI¼ bovine pancreatic trypsin inhibitor
CS¼ connecting segment
CTD¼C-terminal domain
LCI¼ leech carboxypeptidase inhibitor
LDTI¼ leech-derived tryptase inhibitor
MCoTI-II¼Momordica cochinchinensis trypsin
inhibitor II
N¼native protein
NMR¼nuclear magnetic resonance
NTD¼N-terminal domain
PCI¼potato carboxypeptidase inhibitor
R¼ fully reduced and unfolded protein
RNase A¼ ribonuclease A
SLPI¼ secretory leukocyte protease inhibitor
TAP¼ tick anticoagulant peptide
TCI¼ tick carboxypeptidase inhibitor
XS¼molecules with X number of disulfide
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